1/194
Looks like no tags are added yet.
normal aging
mild age-associated cognitive decline
mild cognitive impairmen
Measurable decreases in memory and mental function, but not severe enough to interfere with daily functioning
dementia
Major neurocognitive disorder associated with reduced cognitive abilities in one or more areas of cognitive functioning severe enough that interferes with daily functioning
dementia
umbrella term
-Alzheimer's Disease
-Vascular Dementia
-Lewy Body Dementia
-Frontotemporal Dementia
-Parkinson's Disease
-Neurodegenerative disorders
-Alcholism
-Mixed Dementia
Alzheimer's Dementia (AD) epidemiology
• 2/3 of dementia cases
• 6-8% of older adults
• Prevalence doubles every 5 years after age 60
Vascular Dementia epidemiology
• 15-20% of cases
• Often co-exists with AD ("Mixed dementia")
Dementia with Lewy Bodies (DLB) epidemiology
second most common cause in ppl over 65
etiology of dementia
Accumulation of proteins or protein aggregates within the brain that interrupt neuron signaling (and/or alteration of neurotransmitters - e.g, decreased acetylcholine) and set off a cascade of events affecting neuronal function and cell death in a disease-specific pattern
alzheimer disease
Accumulation of beta amyloid plaques/oligomers outside neurons and twisted strands of tau neurofibrillary tangles inside the neurons
lewy body and Parkinson dementia etiology
abnormal aggregates (or clumps) of cytoplasmic alpha-synuclein ("Lewy body") in neurons in the cortex
frontotemporal dementia etiology
• Nerve cells in the front and temporal (side) lobes of the brain die and the lobes shrink
• Tau or ubiquitin proteins
vascular dementia etiology
Blood vessels in the brain are damaged due to lack of blood, oxygen or nutrients
General Symptoms of dementia
• Memory loss, getting lost
• Difficulty communicating, repeating words and information
• Inability to learn or remember new information
• Difficulty with planning and organizing
• Poor coordination and motor function
• Personality changes
• Inappropriate behavior
• Paranoia, agitation, hallucinations
-BP control
-physical activity
-cognitive training
-education
-glucose control
-healthy diet
What are the probable protective factors for dementia?
-age
-fam hx
-APOE4 allele
-down syndrome
-head trauma
-fewer yrs of formal education
-vascular risk factors (HTN, hypercholesterolemia, diabetes, obesity)
-social isolation and loneliness
What are the risk factors for dementia?
-sleep
-cognitive training
-maintain hearing
-physical activity
-diet: mediterranean diet
-avoid social isolation
-higher level of education
What are some tips for healthy aging?
no not unless an autopsy is conducted post-mortem
Can you make a definitive dx of the cause and type of dementia?
exclusion
Dementia is a dx of _________
-obtain through hx
-perform cognitive test
-rule out causes of memory impairment which could be reversible (drug induced, B12 deficiency, depression, infection, HIV, neurosyphilis, meningitis, normal pressure hydrocephalus, folic acid deficiency, hypoglycemia, hemorrhage, stroke, etc)
-labs
-biomarkers
-neuroimaging (noncontrast CT head scan, MRI, PET or FDG-PET (radioactive tracers), Amyloid PET rules out hematoma, stroke, hemorrhage, structural lesions
How do you dx dementia?
Alzheimer's biomarker
-plasma p-tau217: phosphorylated form for the tau protein
-CSF profile: AB42 (protein fragment that forms plaques in the brain)
-low AB43/40 ratio, high p-tau, and high total tau (sensitivity and specificity are about 85-90%)
• CBC
• Electrolytes
• BUN/SCr
• Fasting glucose
• Liver function tests
• Folic acid
• Homocysteine/methylmalonic acid
• Urinalysis/Toxicology
• Thyroid function tests
• CSF analysis
• HIV testing
• PRP
• Vitamin B12 level
What are the commonly ordered labs?
Alzheimer's amyloid pathology likely
Plasma p-tau217- sensitivity and specificity 88-89% positive (high value)
confirmation with CSF (lumbar puncture) AB42 or amyloid PET
Plasma p-tau217- sensitivity and specificity 88-89% intermediate
Alzheimer's unlikely
Plasma p-tau217- sensitivity and specificity 88-89% negative (low value)
-Antiemetics (promethazine)
-Antidepressants (especially TCAs)
-Antihistamines/Anticholinergics (diphenhydramine, doxylamine)
-Antipsychotics (chlorpromazine, aripiprazole)
-Barbituates (phenobarbital, butalbital)
-Benzos (alprazolam, clonazepam) and non-BZD hypnotics
-Central anticholinergics (benztropine)
-Peripheral anticholinergics (incontinence and IBS drugs)
-Skeletal muscle relaxants (baclofen)
-other CNS depressants (opioids, sedative hypnotics)
What drugs can worsen dementia?
oxybutynin
anticholinergic often used to treat incontinence
diphenhydramine
anticholinergic often used to treat allergies or insomnia
benztropine, diphenhydramine
anticholinergic often used for dystonic reactions
anticholinergics
Cause acute cognitive impairment
o Occasionally psychosis and hallucinations
o Depends on patients:
-Baseline cognitive function
-Sensitivity to the drug
-Drug clearance
-Number of drugs with additive effects
-Dosing schedule
centrally
You should avoid ________ acting anticholinergics in the elderly
cognitive assessments
-Helpful in diagnosis and monitoring
-Montreal Cognitive Assessment (MoCA)
-Mini-Mental State Exam (MMSE)
-DSM5 criteria
-IADL/ADLS
-used in research (CDR scale)
-used for behaviors (neuropsychiatric inventory quesionnaire)
-language
-education level
-progression of disease
-cognitive domains covered
What are the cognitive assessment selections based on?
Montreal Cognitive Assessment (MoCA)
most sensitive in early disease monitoring and detection
Mini-Mental State Exam (MMSE)
most sensitive in advanced stages (gold standard)
24
A score < ______ on the Mini-Mental State Exam (MMSE) indicates a memory disorder.
IADL/ADLS
more sensitive in monitoring progression
Clinical Dementia Rating (CDR) scale
cognitive assessment used in research
Neuropsychiatric Inventory Questionnaire
cognitive assessment used for behaviors
Mini-Cog
-2 items
-score = 5
-Visuospatial, executive function, recall
St. Louis University Mental Status (SLUMS) Examination
-11 items
-score = 30
-Orientation, recall, calculation,naming, attention, executivefunction
Montreal Cognitive Assessment (MoCA)
-12 items
-score = 30
-Orientation, recall, attention, naming, repetition, verbal fluency,
abstraction, executive function, visuospatial
-Best for identifying early cognitive decline
Folstein Mini-Mental Status Examination (MMSE)
-19 items
-score = 30
-Orientation, registration, attention, recall, naming, repetition, 3-step command, language, visuospatial
-Gold standard - best for monitoring cognitive decline in moderate to severe stages
Functional Activities Questionnaire
-10 items
-score = 30
-Informant based, executive functioning, ADLs, attention, concentration, memory, home safety
Independent Activities of Daily Living
• Using Phones
• Shopping
• Food preparation
• Housekeeping
• Laundry
• Transportation
• Taking medications
• Handling finances
Activities of Daily Living
• Bathing
• Dressing
• Toileting
• Transferring
• Continence
• Feeding
gradual
What is the onset of Alzheimers Disease?
Memory impairment core feature with difficulty learning new information, language, visuospatial
What are the cognitive symptoms of Alzheimers Disease?
rare early, apraxia later
What are the motor symptoms of Alzheimers Disease?
gradual over 8-10 yrs on average
What is the progression of Alzheimers Disease?
possible global atrophy, small hippocampal volumes
What imaging can be done in Alzheimers Disease?
•Amyloid antibodies (MCI/mild)
•Cholinesterase inhibitors (mild-severe)
•Memantine (moderate-severe)
What are the pharmacological txs for Alzheimers Disease?
may be sudden/stepwise
What is the onset of vascular dementia?
depends on anatomy of ischemia, but dysexecutive deficits and slowing common
What are the cognitive symptoms of vascular dementia?
correlates with ischemia
What are the motor symptoms of vascular dementia?
gradual or stepwise with further ischemia
What is the progression of vascular dementia?
cortical or subcortical changes on MRI
What imaging can be done for vascular dementia?
•Cholinesterase inhibitors (for memory deficits only)
•Vascular risk reduction
What are the pharmacological txs for Vascular Dementia?
Gradual (typically presents with visual hallucinations, REM sleep behavior disorder)
What is the onset of dementia with lewy bodies?
memory, visuospatial, hallucinations, fluctuating symptoms
What are the cognitive symptoms of dementia with lewy bodies?
parkinsonism
What are the motor symptoms with dementia with lewy bodies?
gradual, but faster than AD
What is the progression of dementia with lewy bodies?
possible global atrophy
What is the imaging for dementia with lewy bodies?
Cholinesterase inhibitors +/- carbidopa-levodopa for movement
What is the pharmacological tx for dementia with lewy bodies?
gradual, usually < 60
What is the onset of frontrotemporal demenita?
executive, disinhibition, apathy, language, +/- memory
What are the cognitive symptoms of frontrotemporal demenita?
none (rare genetic forms associated with ALS)
What are the motor symptoms with frontrotemporal dementia?
gradual, but faster than AD
What is the progression of frontrotemporal dementia?
atrophy in frontral and temporal lobes
What is the imaging for frontrotemporal dementia?
non recommended with current evidence
What are the pharmacologic txs for frontrotemporal dementia?
Alzheimer's Disease
abnormal deposits of proteins from amyloid plaques and tau tangles throughout the brain
frontotemporal dementia
abnormal amounts or forms of tau and TDP-43 proteins accumulate inside neurons in the frontal and temporal lobes
lewy body dementia
Abnormal deposits of the alpha-synuclein protein, called "Lewy bodies," affect the brain's chemical messengers
vascular dementia
conditions, such as blood clots, disrupt blood flow in the brain
preclinical AD
no symptoms but possible biological changes in the brain
mild cognitive impairment due to AD
very mild symptoms that may not interfere with every day activites
dementia due to AD mild
symptoms interfere with some everyday activities
dementia due to AD moderate
symptoms interfere with many everyday activities
dementia due to AD severe
symptoms interfere with most everyday activities
stage 1 dementia
-No cognitive impairment
-Unimpaired individuals experience no memory problems, and none is evident to a health care professional during a medical
interview.
stage 2 dementia
-Very mild cognitive decline
-Individuals at this stage feel as if they have memory lapses, especially in forgetting familiar words or names or the locatio n of keys, eyeglasses, or other everyday objects. However, these problems are not evident during a medical examination or apparent to friends, family, or coworkers.
stage 3 dementia
-Mild cognitive decline
-Early-stage Alzheimer disease can be diagnosed in some, but not all, individuals with these symptoms.
-Friends, family, or coworkers begin to notice deficiencies. Problems with memory or concentration may be measurable in clinic al testing or discernible during a detailed medical interview. -Common difficulties include the following:
-Word- or name-finding problems noticeable to family or close associates
-Decreased ability to remember names when introduced to new people
-Performance issues in social or work settings noticeable to family, friends, or coworkers
-Reading a passage and retaining little material
-Losing or misplacing a valuable object
-Decline in ability to plan or organize
stage 4 dementia
-Moderate cognitive decline (mild or early-stage Alzheimer disease)
-At this stage, a careful medical interview detects clear-cut deficiencies in the following areas:
-Decreased knowledge of recent occasions or current events
-Impaired ability to perform challenging mental arithmetic, eg, to count backward from 100 by 7s
-Decreased ability to perform complex tasks, such as shopping, planning dinner for guests, or paying bills and managing finances
-Reduced memory of personal history
-The affected individual may seem subdued and withdrawn, especially in socially or mentally challenging situations.
stage 5 dementia
-Moderately severe cognitive decline (moderate or mid-stage Alzheimer disease)
-Major gaps in memory and deficits in cognitive function emerge. Some assistance with day -to-day activities becomes essential. At
this stage, individuals may:
-Be unable during a medical interview to recall such important information as their current address, their telephone number, o r
the name of the college or high school from which they graduated
-Become confused about where they are or about the date, day of the week, or season
-Have trouble with less challenging mental arithmetic, e.g., counting backward from 40 by 4s or from 20 by 2s
-Need help choosing proper clothing for the season or occasion
-Usually retain substantial knowledge about themselves and know their own name and the names of their spouse or children
-Usually require no assistance with eating or using the toilet
stage 6 dementia
-Severe cognitive decline (moderately severe or mid-stage Alzheimer disease)
-Memory difficulties continue to worsen, significant personality changes may emerge, and affected individuals need extensive h elp with customary daily activities. At this stage, individuals may:
-Lose most awareness of recent experiences, events, and surroundings
-Recollect their personal history imperfectly, although they generally recall their own name
-Occasionally forget the name of their spouse or primary caregiver but generally can distinguish familiar from unfamiliar face
-Need help getting dressed properly; without supervision, may make errors such as putting pajamas over daytime clothes or shoes on wrong feet
-Experience disruption of their normal sleep-wake cycle
-Need help with handling details of toileting (flushing toilet, wiping, and disposing of tissue properly)
-Have increasing episodes of urinary or fecal incontinence
-Experience significant personality changes and behavioral symptoms, including suspiciousness and delusions (eg, believing that their caregiver is an impostor); hallucinations (seeing or hearing things that are not really there); or compulsive, repetitive
behaviors such as hand wringing or tissue shredding
-Tend to wander and become lost
stage 7 dementia
-Very severe cognitive decline (severe or late-stage Alzheimer disease)
-This is the final stage of the disease when individuals lose the ability to respond to their environment, to speak, and ultim ately to
control movement.
-Frequently lose the ability for recognizable speech, although words or phrases may occasionally be uttered
-Need help with eating and toileting, and there is general urinary incontinence
-Lose the ability to walk without assistance, then the ability to sit without support, smile, and to hold up head; reflexes be come
abnormal, muscles grow rigid, and swallowing is impaired
• Manage dementia related cognitive, behavioral, and psychosocial issues
• Enhance quality of life and maximize functional performance by improving or stabilizing cognition, mood, and behavior
• Recognize acute changes and factors that contribute to behavioral changes
What are the goals of tx in dementia?
non-pharm tx of dementia
• Cognitive Training
• Supportive individual and group therapy
• Physical and mental activity
• Family and caregiver education and support
• Safety monitoring
o ADL/IADL oversight, wandering, driving, etc
• Environmental modifications
o Supportive strategies such as clocks, calendars, to-do lists, visual clues, simple and compassionate communication styles
o Structure activities to match patient abilities
• Vitamin E 2,000 IU daily - inconsistent findings
• Ginkgo Biloba - increases risk of bleeding
• Apoaequorin (Prevagen) - increases risk of stroke
• Coral calcium
• Coenzyme Q10
• Phosphatidylserine
What are the natural products "used for dementia" but should be avoided and are NOT recommended?
Amyloid-beta antibodies
o Lecanemab (Leqembi)
o Donanemab (Kinsula)
Leqembi
Lecanemab
Kinsula
Donanemab
Acetylcholinesterase inhibitors
o Donepezil (Aricept)
o Galantamine (Razadyne)
o Rivastigmine (Exelon)
Aricept
donepezil
Razadyne
galantamine
Exelon
rivastigmine
Namena
memantine
Namzaric
donepezil + memantine
NMDA receptor blocker
Memantine (Namenda)
symptom
Acetylcholinesterase inhibitors and NMDA receptor blockers do ___________ management.
- Does not reverse dementia
- May delay progression
- Might modestly delay cognitive decline, delay onset of behaviors, maintain ADLs longer
reduction in beta amyloid plaque distribution on PET imaging, but
clinical correlation in delay in disease progression appears to limited to those in the very early stages of disease. Significant
side effects and cost.
Why are amyloid-beta antibodies controversial?